These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 11113067)

  • 21. Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease.
    Sands BE; Jacobson EW; Sylwestrowicz T; Younes Z; Dryden G; Fedorak R; Greenbloom S
    Inflamm Bowel Dis; 2010 Jul; 16(7):1209-18. PubMed ID: 19918967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease.
    Mantzaris GJ; Christidou A; Sfakianakis M; Roussos A; Koilakou S; Petraki K; Polyzou P
    Inflamm Bowel Dis; 2009 Mar; 15(3):375-82. PubMed ID: 19009634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group.
    Stange EF; Modigliani R; Peña AS; Wood AJ; Feutren G; Smith PR
    Gastroenterology; 1995 Sep; 109(3):774-82. PubMed ID: 7657105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease.
    Thiele K; Bierhaus A; Autschbach F; Hofmann M; Stremmel W; Thiele H; Ziegler R; Nawroth PP
    Gut; 1999 Nov; 45(5):693-704. PubMed ID: 10517905
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor.
    Dieckgraefe BK; Korzenik JR
    Lancet; 2002 Nov; 360(9344):1478-80. PubMed ID: 12433518
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group.
    Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL
    Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Randomized, placebo-controlled, double-blind trial of Boswellia serrata in maintaining remission of Crohn's disease: good safety profile but lack of efficacy.
    Holtmeier W; Zeuzem S; Preiss J; Kruis W; Böhm S; Maaser C; Raedler A; Schmidt C; Schnitker J; Schwarz J; Zeitz M; Caspary W
    Inflamm Bowel Dis; 2011 Feb; 17(2):573-82. PubMed ID: 20848527
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prior bowel resections, perianal disease, and a high initial Crohn's disease activity index are associated with corticosteroid resistance in active Crohn's disease.
    Gelbmann CM; Rogler G; Gross V; Gierend M; Bregenzer N; Andus T; Schölmerich J
    Am J Gastroenterol; 2002 Jun; 97(6):1438-45. PubMed ID: 12094862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Ustekinumab for Inducing Endoscopic Healing in Patients With Crohn's Disease.
    Rutgeerts P; Gasink C; Chan D; Lang Y; Pollack P; Colombel JF; Wolf DC; Jacobstein D; Johanns J; Szapary P; Adedokun OJ; Feagan BG; Sandborn WJ
    Gastroenterology; 2018 Oct; 155(4):1045-1058. PubMed ID: 29909019
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of efficacy of ridogrel, a thromboxane synthase inhibitor, in a placebo-controlled, double-blind, multi-centre clinical trial in active Crohn's disease.
    Carty E; Rampton DS; Schneider H; Rutgeerts P; Wright JP
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1323-9. PubMed ID: 11552902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sargramostim (GM-CSF) for induction of remission in Crohn's disease.
    Roth L; Macdonald JK; McDonald JW; Chande N
    Cochrane Database Syst Rev; 2011 Nov; (11):CD008538. PubMed ID: 22071853
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase 2 study of allogeneic mesenchymal stromal cells for luminal Crohn's disease refractory to biologic therapy.
    Forbes GM; Sturm MJ; Leong RW; Sparrow MP; Segarajasingam D; Cummins AG; Phillips M; Herrmann RP
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):64-71. PubMed ID: 23872668
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Defining the optimal response criteria for the Crohn's disease activity index for induction studies in patients with mildly to moderately active Crohn's disease.
    Thia KT; Sandborn WJ; Lewis JD; Loftus EV; Feagan BG; Steinhart AH; Hanauer SB; Persson T; Sands BE
    Am J Gastroenterol; 2008 Dec; 103(12):3123-31. PubMed ID: 18786111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclosporine for induction of remission in Crohn's disease.
    McDonald JW; Feagan BG; Jewell D; Brynskov J; Stange EF; Macdonald JK
    Cochrane Database Syst Rev; 2005 Apr; (2):CD000297. PubMed ID: 15846602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease.
    Reinisch W; Hommes DW; Van Assche G; Colombel JF; Gendre JP; Oldenburg B; Teml A; Geboes K; Ding H; Zhang L; Tang M; Cheng M; van Deventer SJ; Rutgeerts P; Pearce T
    Gut; 2006 Aug; 55(8):1138-44. PubMed ID: 16492717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
    Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
    J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Why interleukin-10 supplementation does not work in Crohn's disease patients.
    Marlow GJ; van Gent D; Ferguson LR
    World J Gastroenterol; 2013 Jul; 19(25):3931-41. PubMed ID: 23840137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.